<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464177</url>
  </required_header>
  <id_info>
    <org_study_id>RT-01/2011</org_study_id>
    <nct_id>NCT01464177</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme</brief_title>
  <acronym>GBM Hypo RT</acronym>
  <official_title>Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andre Tsin Chih Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The treatment
      comprises maximal safe resection followed by radiotherapy and chemotherapy. Despite
      appropriate management, 90% of the patients will develop relapse or progression. After
      progression, the median survival is 5.2 months (Stupp, 2009).

      The treatment of GBM relapse remains investigational. Reirradiation is an option in selected
      cases.

      The objective of this study is to compare 2 schemes of stereotactic hypofractionated
      radiotherapy in the management of recurrent GBM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>from date of randomization until date of first documented progression or death from any cause, which ever comes first, assessed up to 48 months</time_frame>
    <description>progression free survival as defined by the &quot;Response Assesment in Neuro Oncology Working Group&quot;(Wen, 2010). Briefly progression is defined as:
increase in 25% of the product of perpendicular diameters of enhancing lesions
significant increase in T2/Flair non enhancing component
appearance of new lesions
clinical deterioration not atributable to other causes other than the tumor or reduction in corticosteroid dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from date of randomization until death from any cause, assessed up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>from date of randomization until date of local progression, assessed up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>from date of randomization until death, assessed up to 48 months</time_frame>
    <description>toxicity scored by the Common Terminology of Adverse Events version 4
will be assessed every 2 months or in case of patient hospitalization or visit to the E.R.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>from date of randomization until last follow-up, assessed up to a period of 48 months</time_frame>
    <description>quality of life measured by the &quot;FACT Br&quot; questionary
will be assessed every 2 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Recurrent Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Stereotactic hypofractionated RT 5x5Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
the dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic hypofractionated RT 5x7Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
the dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic hypofractionated RT 5x5Gy</intervention_name>
    <description>Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization</description>
    <arm_group_label>Stereotactic hypofractionated RT 5x5Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic hypofractionated RT 5x7Gy</intervention_name>
    <description>Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization.</description>
    <arm_group_label>Stereotactic hypofractionated RT 5x7Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  KPS equal or greater than 60

          -  Anatomopathological confirmation of GBM

          -  Previous RT with therapeutic doses

          -  At least 5 months from the end of RT course

          -  Not a candidate to surgical resection

          -  Patients with partial resection after resection of recurrent GBM will be allowed

          -  Patients with local progression after resection of recurrent GBM will be allowed

          -  Lesion with a maximal 150cc volume, as defined by enhancing portion in contrast
             enhanced MRI

          -  Hemoglobin levels (Hb) equal or greater than 10ng/dl. Blood transfusions to correct
             the Hb will be allowed.

        Exclusion Criteria:

          -  Important comorbidities

          -  Concomitant chemotherapy

          -  Contraindication to MRI

          -  Brainstem glioma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre T Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas da Faculdade de Medicina da USP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andre T Chen, M.D.</last_name>
    <phone>55-11-2661-7081</phone>
    <email>andre.chen@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Weltman, M.D./PhD</last_name>
    <phone>55-11-2661-7089</phone>
    <email>eweltman@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre T Chen, M.D.</last_name>
      <phone>55-11-2661-7081</phone>
      <email>andre.chen@hc.fm.usp.br</email>
    </contact>
    <investigator>
      <last_name>Andre T Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.</citation>
    <PMID>19269895</PMID>
  </reference>
  <reference>
    <citation>Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C. Therapeutic options for recurrent malignant glioma. Radiother Oncol. 2011 Jan;98(1):1-14. doi: 10.1016/j.radonc.2010.11.006. Epub 2010 Dec 13. Review.</citation>
    <PMID>21159396</PMID>
  </reference>
  <reference>
    <citation>Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8.</citation>
    <PMID>9069312</PMID>
  </reference>
  <reference>
    <citation>Vordermark D, KÃ¶lbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005 May 30;5:55.</citation>
    <PMID>15924621</PMID>
  </reference>
  <reference>
    <citation>Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol. 2007 Feb;81(3):287-94. Epub 2006 Sep 20.</citation>
    <PMID>17031558</PMID>
  </reference>
  <reference>
    <citation>Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010 Jun 20;28(18):3048-53. doi: 10.1200/JCO.2009.25.6941. Epub 2010 May 17. Erratum in: J Clin Oncol. 2010 Sep 20;28(27):4280.</citation>
    <PMID>20479391</PMID>
  </reference>
  <reference>
    <citation>Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol. 2009 Apr;185(4):235-40. doi: 10.1007/s00066-009-1753-x. Epub 2009 Apr 16.</citation>
    <PMID>19370426</PMID>
  </reference>
  <reference>
    <citation>Cheng JX, Zhang X, Liu BL. Health-related quality of life in patients with high-grade glioma. Neuro Oncol. 2009 Feb;11(1):41-50. doi: 10.1215/15228517-2008-050. Epub 2008 Jul 15. Review.</citation>
    <PMID>18628405</PMID>
  </reference>
  <reference>
    <citation>Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol. 2009 Jun;11(3):330-9. doi: 10.1215/15228517-2008-093. Epub 2008 Nov 10. Review.</citation>
    <PMID>19001097</PMID>
  </reference>
  <reference>
    <citation>Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.</citation>
    <PMID>20231676</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2011</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Andre Tsin Chih Chen</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>malignant glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

